OQROGet OQRO Pro
Insider trade

Jazz Pharmaceuticals (JAZZ)Director sold ~$1.38M

Bruce C Cozadd, Director at Jazz Pharmaceuticals, sold ~$1.38M of Jazz Pharmaceuticals shares.

~$1.38M
Approx. value · 6,000 sh @ $230.33
346K
Holds after · shares reported
Traded
Oct 1, 2026
Filed
Oct 6, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 3, 2026Company filing · Form 8-K · ResultsReported its results
  2. Aug 3, 2026InsiderDirector sold ~$1.52M of JAZZ shares in the open market
  3. Aug 10, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  4. Aug 26, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
  5. Aug 27, 2026Insider · 1 personInsiders: 6 sales (~$19.2M)
  6. Sep 1, 2026InsiderDirector sold ~$1.5M of JAZZ shares in the open market
  7. Sep 8, 2026InsiderCEO sold ~$486K of JAZZ shares in the open market
  8. Sep 10, 2026InsiderOfficer sold ~$289K of JAZZ shares in the open market
  9. Sep 23, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  10. Oct 1, 2026 · this disclosureInsiderDirector sold ~$1.38M of JAZZ shares in the open market

What came next

  1. Oct 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company” ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027.”
  2. Oct 6, 2026InsiderCEO sold ~$473K of JAZZ shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Jazz Pharmaceuticals

For Jazz Pharmaceuticals, OQRO holds 14 insider filings (SEC Form 4 or Form 144) and 10 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JAZZ page.

Other recent filings by Bruce C Cozadd, Director

The full history of Bruce C Cozadd, Director is on the profile page.

How this filing works

Other disclosures at Jazz Pharmaceuticals

Everything OQRO holds on this company is on its JAZZ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data